Upregulation of Versican Associated with Tumor Progression, Metastasis, and Poor Prognosis in Bladder Carcinoma

Table 1

Relationship of VCAN expression with pathological parameters of bladder cancer.

Clinical parameters	VCAN expression
	Low	High
Gender			0.859	0.354
Male	106 (29.0%)	260 (71.0%)
Female	18 (35.3%)	33 (64.7%)
Age (yrs)			0.823	0.364
<60	42 (27.1%)	113 (72.9%)
≥60	82 (31.3%)	180 (68.7%)
Size			3.597	0.058
<3 cm	71 (34.0%)	138 (66.0%)
≥3 cm	53 (25.5%)	155 (74.5%)
Number of tumors			13.189	0.000
Single	40 (45.5%)	48 (54.5%)
Multiple	84 (37.5%)	245 (62.5%)
Invasion depth			17.657	0.000
Ta-T1	32 (52.5%)	29 (47.5%)
T2-T4	92 (25.8%)	264 (74.2%)
Lymph node metastasis			11.039	0.001
No	107 (34.0%)	208 (66.0%)
Yes	17 (16.7%)	85 (83.3%)
Distant metastasis			6.129	0.013
No	120 (31.4%)	262 (68.6%)
Yes	4 (11.4%)	31 (88.6%)
Lymphovascular invasion			3.648	0.056
Negative	119 (31.0%)	265 (69.0%)
Positive	5 (15.2%)	28 (84.8%)
Histological grade			10.577	0.005
Low grade (superficial)	52 (35.4%)	95 (64.6%)
High grade (infiltrating)	72 (26.7%)	198 (73.3%)
TNM stage			4.842	0.184
I	33 (31.4%)	72 (68.6%)
II	24 (24.0%)	76 (76.0%)
III	39 (27.9%)	101 (72.1%)
IV	28 (38.9%)	44 (61.1%)